Alkermes (ALKS)
(Delayed Data from NSDQ)
$29.24 USD
+0.01 (0.03%)
Updated Nov 13, 2024 04:00 PM ET
After-Market: $29.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.24 USD
+0.01 (0.03%)
Updated Nov 13, 2024 04:00 PM ET
After-Market: $29.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum B VGM
Zacks News
Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24 cents.
5 Drug Stocks for Your Portfolio this World Health Day
by Arpita Dutt
With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.
Alkermes Starts Phase III Study to Treat Multiple Sclerosis
by Zacks Equity Research
Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.
5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices
by Zacks Equity Research
For those who thought that the pharma/biotech sector is in for an extraordinary run after Donald Trump's unexpected victory, his latest vow to crack down on excessive drug price hikes comes as a bolt from the blue.